

REMARKS/ARGUMENTS

Reconsideration of this application is requested. Claims 1-9, 13, and 15-19 will be pending in the application subsequent to entry of this Amendment.

The claims have been amended in order to more particularly point out and distinctly claim that which applicants regard as their invention, to address various issues raised in the outstanding Official Action and to advance prosecution generally. The claims directed to compounds have been revised to state a compound in the singular, claims 10-12 and 14 have been deleted in order to advance examination and "use of ..." claims 16-18 have been recast as in method format. New claim 19 has been added; *see* page 4, second full paragraph of the description and compare with page 2, item 4, second sentence of the Official Action.

The issues raised in the outstanding Official Action are addressed below in the order presented:

4. Claims 14-18 – 35 U.S.C. § 112 paragraph 1 (enablement)

The applicants duly considered this objection, but they cannot agree with it.

Camptothecins are a well-known class of antitumor drugs used for the treatment of different tumors. The description of the invention makes explicit reference to EP 1 044 977 (EP '977), of record and the literature cited therein. This reference reports that camptothecins demonstrated a wide spectrum of antitumor activity, in particular against colon tumors, other solid tumors and leukemias (see page 1, fourth paragraph). The clinical reference for camptothecins is Topotecan, which is indicated for the treatment of small and non-small cell lung, ovarian, breast, stomach, liver, prostatae, soft tissue sarcoma, head and neck, oesophagus, resistant colon-rectum, multiform glioblastoma, chronic and acute myelocytic leukemias (EP'977, page 3, third paragraph). The compounds disclosed in EP'977, of which the compounds of the present invention are derivatives as far as the 7-C(R₅)=N-O-R₄ substituent is concerned, and the activity on a wide range of tumors is proved by the enclosed list of references retrieved from PubMed (ENCLOSURE 1). See also Penco et al., US 6,242,457 (of record), claiming priority of EP'744, where the range of treated tumors was expanded (column 14).

Further evidence of a wide range of antitumor activity is found in the same references cited by the examiner, see WO 97/00876, page 23, third full paragraph.

Therefore, the state of the art should be fully taken into account, since there is no reason to believe that the claimed compounds are not effective on different tumors. To the contrary, the problem solved by the present invention is to enhance stability of the molecule, thus enhancing the pharmacological activity gives a person skilled in the art a more powerful therapeutic tool.

The present compounds are not claimed for treating tumors which are not usually treated with Topoisomerase I inhibitors or with camptothecins in general. This is very clear from the whole content of the description and the references cited therein. Therefore, the skilled reader will know for which type of tumors the compounds can be used.

Activity of camptothecins in parasitic and viral infections is well-known in the art (see WO'876, page 23, first full paragraph).

In view of the above, applicants respectfully request withdrawal of this rejection.

6. Claims 1-18 – 35 USC §112, paragraph 2 (claim clarity)

Amended claim 1 is corrected above with the correct formula (I) inserted in place of the previous one. The editing error is evident from the content of the description, in particular see page 10, synthesis scheme, Examples and list of preferred compounds. Nothing more than camptothecin derivatives was originally intended by the applicants and this correction offered is to adjust the claim and clarify the record.

The Reformatsky reaction is a well-known method for lengthening the carbon chain of carboxylic acids, a page from a university organic chemistry handbook is enclosed (ENCLOSURE 2) to confirm this.

Claim 7 has been corrected and applicants thank the Examiner for pointing out the error.

Claim 12 has been deleted, thus rendering the objection moot.

Claim 14 has been deleted, thus rendering the objection moot.

Claim 15 is maintained but amended to depend from claim 13. Applicants believe this claim is clear to the skilled reader, since combining different antitumor drugs is common knowledge and practice in this field. The other antitumor drug will be determined by the skilled clinician simply exercising his or her knowledge.

Claims 17 and 18 are maintained, since applicants believe that the skilled person will know how to use the invention just resorting to common knowledge. A sample of relevant literature is enclosed (ENCLOSURE 3).

8. Claims 11 and 16-18 – 35 U.S.C. § 101

Claim 11 is deleted as being non-statutory.

Claims 16-18 have been amended and cast as method claims. Claim 19 is added and is directed to specify a type of tumor.

9.-10. Claims 1-3, 6, 7 and 12-18 – 35 U.S.C. § 102(b)

Claim 1 has been further amended by introducing a proviso to disclaim compounds specifically disclosed by Bigg et al.

Claim 10 has been deleted, thus rendering the objection moot.

13. Claims 1-4 and 12-18 – 35 U.S.C. § 103(a) – Penco in view of Bom

Applicants acknowledge the cited references are relevant to the above claims. However, the cited references do not lead the skilled person to the claimed invention for at least the following reasons.

Bom et al. disclose camptothecins having modified lactone ring, but the characteristic feature of Bom et al. compounds is the substituent in position 7, which is a silyl derivative. The Bom et al. teaching is limited to this feature, since the title of their work, Bom et al. declare that lipophilicity is the essential characteristic of their camptothecin derivatives (Novel A,B,E-Ring-Modified Camptothecins Displaying High Lipophilicity and Markedly Improved Human Blood Stabilities – emphasis added).

The primary reference, Penco et al., provided a new class of camptothecin derivatives, which are camptothecin 7-substituted oximes. These compounds were successfully patented notwithstanding the technical prejudice existing in the art at that time that camptothecin activity was proportional to the lipophilic character of the 7-substituent (Penco et al., col. 4, lines 32-51, in particular lines 49-50). The technical prejudice was represented by the authoritative Sawada et

al. paper cited in the passage mentioned here; this paper refers back to US 4,399,276, cited both in Penco et al. and in the present circumstance of this application.

The Bom et al. paper was published in 1999, the same year of Penco et al's priority date. This indicates that Bom et al. were not aware of Penco et al's patent (published in 2001), but were aware of Sawada US'276 (published in 1983) thus they plainly followed the state of the art teaching to provide highly lipophilic substituent in position 7 of camptothecin skeleton.

Penco et al. are not concerned with the problem of stabilizing the lactone ring, but rather in the problem of low water solubility, gastrointestinal and bone marrow side effects, resistance against topoisomerase I inhibitors by certain tumor lines and how to improve therapeutic index (column 3, last paragraph to column 4, line 1).

Penco et al. fully succeeded in improving therapeutic index (column 4, lines 62-64; column 13) and water solubility (column 13, lines 31, injectable formulations).

The skilled person will understand that the modification at position 7 with a lower lipophilic group, such as a substituted oxime (the same as in the present compounds) enhances therapeutic index through the increase of the persistence of DNA cleavage stimulated by camptothecins and mediated by topoisomerase I (see column 13, lines 35-67).

Bom et al. note an antitumor activity which is not much better than that of camptothecin, one of the less effective compounds of this family due to very low water solubility (Penco et al., column 1, lines 17-28). This comparison is not very significant, since the best Bom et al compound DB-38 is worse than camptothecin; see the corresponding WO 00/61146, page 55, cited in the present application together with the Bom et al's paper cited by the Examiner. In any case, the increase (?) of activity is explained with the improved stability of the lactone ring.

The person skilled in the art, with the problem of improving stability of Penco et al.'s camptothecins will find in Bom et al. the indication that lactone ring can be expanded in highly lipophilic camptothecins (bearing a highly lipophilic substituent in position 7).

The person skilled in the art knows that the lipophilicity-lowering modification made by Penco et al. to lipophilic camptothecins of Sawada (US'276) improves antitumor activity by enhancing persistence of DNA cleavage stimulated by camptothecins and mediated by topoisomerase I.

This person also knows that antitumor activity is at least maintained (not increased) in camptothecins substituted in position 7 with a highly lipophilic group by enlarging the lactone ring from 6 to 7 members in order to increase plasma stability.

It is evident that the two teachings do not agree with each other. Penco et al. teach how to improve the intracellular phenomenon of DNA cleavage, whereas Bom et al. teach to improve plasma stability.

There is no indication that applying Bom et al.'s teaching to Penco et al.'s the goal of still achieving a better therapeutic index would be met (present application, page 3, second paragraph). To the contrary, it does not seem that the improved plasma stability achieved by Bom et al. increases antitumor activity.

Quite surprisingly, the present invention provides compounds with extremely higher activity (see page 15, Table 1). Therefore, there is no teaching at all in Bom et al. that the lactone ring modification barely maintaining antitumor activity with respect to a well-known poorly effective compound (camptothecin) would provide a camptothecin derivative with increased activity.

Applicants respectfully request acknowledgment of non obviousness of the claimed subject-matter and withdrawal of the objection.

14. Claims 1-4 and 12-18 – 35 U.S.C. § 103(a) – Dallavalle

Dallavalle et al. is not available as prior art thus cannot be considered in the examination of the present invention. Dallavalle et al. bears a publication date of June 2002, but likely made available to the public even later.

The present application enjoys a priority date of May 31, 2002, clearly before Dallavalle et al. was published.

Applicants respectfully request withdrawal of the rejection.


For the above reasons it is respectfully submitted that the claims of this application define inventive subject matter. Reconsideration and allowance are solicited.

MARZI, Mauro et al.
Appl. No. 10/511,724
March 3, 2006

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____




Arthur R. Crawford
Reg. No. 25,327

ARC:eaw
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100



PubMed
www.pubmed.gov

A service of the National Library of Medicine
and the National Institutes of Health

My NCBI 
[Sign in] [Register]

Search PubMed

for gimatecan

Save Search

Limits Preview/Index History Clipboard Details

Display Summary Show 20 Sort by Send to


All: 18 Review: 3 

Items 1 - 18 of 18


One page.

Related Articles, Links

☐ 1: Perego P, Ciusani F, Gatti J, Carenni N, Corni E, Zunino F.


 Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate carcinoma cells.
Biochem Pharmacol. 2006 Jan 23; [Epub ahead of print]
PMID: 16438941 [PubMed - as supplied by publisher]

☐ 2: Wakelee HA, Sikic BI.

 Activity of novel cytotoxic agents in lung cancer: cpothilones and topoisomerase I inhibitors.
Clin Lung Cancer. 2005 Sep;7 Suppl 1:S6-12. Review.
PMID: 16159420 [PubMed - indexed for MEDLINE]


Related Articles, Links

☐ 3: Di Francesco AM, Riccardi A, Barone G, Rutella S, Mayo D, Frapolli R, Zucchetti M, Vinciguerra M, Pisano C, Cammelli P, Riccardi R.

 The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan.
Biochem Pharmacol. 2005 Oct 15;70(8):1125-36. Erratum in: Biochem Pharmacol. 2005 Dec 5;70(12):1891. Riccardi, Anna Shirley [corrected to Riccardi, Anna].
PMID: 16139802 [PubMed - indexed for MEDLINE]


Related Articles, Links

☐ 4: Nitiss JL, Nitiss KC.

 Gimatecan (sigma-tau industrie farmaceutiche riunite/novartis).
IDrugs. 2005 Jul;8(7):578-88. Review.
PMID: 15973567 [PubMed - in process]


Related Articles, Links

☐ 5: De Cesare M, Perego P, Righetti SC, Pratesi G, Carenni N, Rivoltini L, Zupi G, Del Bufalo D, Balsani A, Zunino F.

 Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts.
Eur J Cancer. 2005 May;41(8):1213-22.
PMID: 15911246 [PubMed - indexed for MEDLINE]


Related Articles, Links

☐ 6: Ullio P, Zoli W, Fabbri F, Brigliadori G, Riccio L, Tassi A, Rosati M, De Cesare M, Barone G, Costa E, Zunino F.

 Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models.
Neoplasia. 2005 Feb;7(2):152-61.
PMID: 15802020 [PubMed - indexed for MEDLINE]


Related Articles, Links

☐ 7: Bayes M, Rabasseda X, Prous JS.

 Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2004 Nov;26(9):723-53.
PMID: 15632957 [PubMed - indexed for MEDLINE]


Related Articles, Links

☐ 8: De Cesare M, Pratesi G, Veneroni S, Bergantini R, Zunino F.

 Efficacy of the novel camptothecin gimatecan against orthotopic and metastatic human tumor xenograft models.
Clin Cancer Res. 2004 Nov 1;10(21):7357-64.
PMID: 15534112 [PubMed - indexed for MEDLINE]

Related Articles, Links

☐ 9: Stano P, Bufali S, Pisano C, Bucci E, Barbarino M, Santamello M, Cammelli P, Lorus PL.

 Novel camptothecin analogue (gimatecan)-containing liposomes prepared by the ethanol injection method.
J Liposome Res. 2004;14(1-2):87-109.
PMID: 15461935 [PubMed - indexed for MEDLINE]










Related Articles, Links

☐ 10: Pratesi G, Barone G, Zunino F.

Related Articles, Links

Gimatecan, a novel camptothecin with a promising preclinical profile.

BEST AVAILABLE COPY

-  Anticancer Drugs. 2004 Jul;15(6):545-52. Review.
PMID: 15205395 [PubMed - indexed for MEDLINE]
- ☐ 11: Cioci A, Bottrotti G, Supino R, Fayini E, Zucco V, Zunino F Related Articles, Links
 Subcellular localization of the camptothecin analogues, topotecan and gimatecan.
Biochem Pharmacol. 2004 Mar 15;67(6):1035-45.
PMID: 15006540 [PubMed - indexed for MEDLINE]
- ☐ 12: Perrangolini G, Pratesi G, De Cesare M, Supino R, Pisano C, Marcellini M, Giordano V, Iacchione D, Lunzi C, Zunino F Related Articles, Links
 Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts.
Mol Cancer Res. 2003 Oct;1(12):863-70.
PMID: 14573787 [PubMed - indexed for MEDLINE]
- ☐ 13: Bayes M, Rabusseda X, Prous JR Related Articles, Links
 Gateways to clinical trials.
Methods Find Exp Clin Pharmacol. 2003 Jul-Aug;25(6):483-506.
PMID: 12949633 [PubMed - indexed for MEDLINE]
- ☐ 14: Bayes M, Rabusseda X, Prous JR Related Articles, Links
 Gateways to clinical trials. March 2003.
Methods Find Exp Clin Pharmacol. 2003 Mar;25(2):145-68.
PMID: 12731460 [PubMed - indexed for MEDLINE]
- ☐ 15: Zucco V, Supino R, De Cesare M, Carcinini N, Perego P, Gatti L, Pratesi G, Pisano C, Martinelli R, Bucci F, Zanier R, Carminati P, Zunino F Related Articles, Links
 Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models.
Biochem Pharmacol. 2003 Apr 15;65(8):1281-94.
PMID: 12694869 [PubMed - indexed for MEDLINE]
- ☐ 16: Pratesi G, De Cesare M, Carcinini N, Perego P, Righetti SC, Cucco C, Merlini L, Pisano C, Penco S, Carminati P, Vesci L, Zunino F Related Articles, Links
 Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
Clin Cancer Res. 2002 Dec;8(12):3904-9.
PMID: 12473606 [PubMed - indexed for MEDLINE]
- ☐ 17: De Cesare M, Pratesi G, Perego P, Carcinini N, Tinelli S, Merlini L, Penco S, Pisano C, Bucci F, Vesci L, Pace S, Capocasa F, Carminati P, Zunino F Related Articles, Links
 Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin.
Cancer Res. 2001 Oct 1;61(19):7189-95.
PMID: 11585754 [PubMed - indexed for MEDLINE]
- ☐ 18: Perego P, De Cesare M, De Ianchella P, Carcinini N, Bignardi G, Pezzoni G, Palumbo M, Tanoglio L, Pratesi G, Pisano C, Carminati P, Scheffer GL, Zunino F Related Articles, Links
 A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line.
Cancer Res. 2001 Aug 15;61(16):6034-7.
PMID: 11507048 [PubMed - indexed for MEDLINE]

Display Summary Show Sort by Send to

[Write to the Help Desk](#)
NCBI | NLM | NIH
Department of Health & Human Services
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

June 19, 2004, 14:31:31

ENCLOSURE 1



PubMed
www.pubmed.gov

A service of the National Library of Medicine
and the National Institutes of Health

My NCBI
(Sign In) (Register)

All Databases

PubMed

PubMed Central

PubMed

PubMed

PubMed

PubMed

PubMed

PubMed

PubMed

Search PubMed

for

Go

Clear

Limits

Preview/Index

History

Clipboard

Details

Display

Abstract

Show 20

Sort by

Send to

All: 1

Review: 1



About Entrez
NCBI Toolbar

Text Version

Entrez PubMed

Overview
Help | FAQ
Tutorials
Now/Noteworthy
E-Utilities

PubMed Services


Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI

Related Resources

Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

☐ 1: Anticancer Drugs. 2004 Jul;15(6):545-52.

Related Articles, Links



Gimatecan, a novel camptothecin with a promising preclinical profile.

Pratesi G, Beretta G.L., Zunino F.

Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy. graziella.pratesi@istitutotumori.mi.it

The realization that position 7 of camptothecin allows several options in chemical manipulation of the drug has stimulated a systematic investigation of a variety of substituents in this position. These efforts resulted in the identification of a novel series of 7-oxyiminomethyl derivatives. Among compounds of this series we have selected a promising lipophilic derivative, gimatecan, for further development. The relevant features of gimatecan are: (i) marked cytotoxic potency, likely related to multiple factors, including a potent inhibition of topoisomerase I, a persistent stabilization of the cleavable complex, an increased intracellular accumulation and a peculiar subcellular localization; (ii) lack of recognition by known resistance-related transport systems; (iii) increased lactone stability and favorable pharmacokinetics; (iv) good oral bioavailability; and (v) an impressive antitumor efficacy in a large panel of human tumor xenografts, with various treatment schedules. Phase I clinical studies with oral administration support the preclinical results of the novel camptothecin. Using different schedules and dosing durations, gimatecan exhibited an acceptable toxicity profile, with myelotoxicity being the dose-limiting toxic effect. An appreciable number of tumor responses was achieved and favorable pharmacokinetics with a very long terminal half-life was observed. The clinical development of gimatecan is currently ongoing, with phase II studies in diverse tumor types (colon, lung, breast carcinoma and pediatric tumors).

Publication Types:

- Review

PMID: 15205595 [PubMed - indexed for MEDLINE]

Display Abstract

Show 20

Sort by

Send to

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)


Jan 19, 2006 01:11:52

BEST AVAILABLE COPY



Chap. 24

Difunctional
Compounds I


When the α -diketone is cyclic, the rearrangement serves as a method of ring contraction.




4. THE REFORMATSKY REACTION. β -Hydroxy esters result when an aldehyde or a ketone is treated with an α -halo ester and zinc in an inert solvent (the Reformatsky reaction).





The reactive intermediate in the Reformatsky reaction is an organozinc reagent that may be regarded as the anion of an ester (Section 18.8), closely associated with a zinc cation. This carbanion has nucleophilic properties and undergoes addition to the carbonyl group of the aldehyde or ketone.



A more recent version of the same reaction utilizes the lithium enolate of an ester, which is prepared by treating the ester with a lithium dialkylamide (Section 18.8). Addition of an aldehyde or ketone gives the β -hydroxy ester in good yield.



5. HYDROLYSIS OF LACTONES. Various hydroxy acids are available by the hydrolysis of lactones, which may be obtained by the Baeyer-Villiger oxidation of cyclic ketones (Section 15.8.A).




B. React

1. FORMA
alcohols unde

A hydroxy ac
intramolecu


Lactonization,
the lactone ha
lactone presen
The data in T
the amount of
Although th
rium with the f
conditions. In
conditions wh
unfavorable eq
dilute solution
leads to a poly



15-hydrox


γ -Lactones ar
often not necess
more traces of :

BEST AVAILABLE COPY



A service of the National Library of Medicine
and the National Institutes of Health

www.pubmed.gov

My NCBI 
(Sign In) (Register)

All Databases

PubMed

Nucleotide

Protein

Gene

Structure

Chem

PMC

Journals

Books

Search PubMed

for "Camptothecin"[MeSH] and (parasitic or viral infect) Save Search

Limits

Preview/Index

History

Clipboard

Details

Display

Summary

Show 50

Sort by

Send to

All: 39


Review 2




Items 1 - 39 of 39

One page.


☐ 1: Kato T, Jeki R, Saito E, Ota T, Yutani K, Igarashi M, Okumura T, Shibuya M. [Related Articles, Links](#)

 A long-term survival case of small cell lung cancer in an HIV-infected patient.
Jpn J Clin Oncol. 2005 Jun;35(6):349-52. Epub 2005 May 31.
PMID: 15928189 [PubMed - indexed for MEDLINE]


☐ 2: Groschel B, Bushman F. [Related Articles, Links](#)

 Cell cycle arrest in G2/M promotes early steps of infection by human immunodeficiency virus.
J Virol. 2005 May;79(9):5695-704.
PMID: 15827184 [PubMed - indexed for MEDLINE]


☐ 3: Marquis JF, Hardy I, Olivier M. [Related Articles, Links](#)

 Topoisomerase I amino acid substitutions, Gly185Arg and Asp325Glu, confer camptothecin resistance in *Leishmania donovani*.
Antimicrob Agents Chemother. 2005 Apr;49(4):1441-6.
PMID: 15793124 [PubMed - indexed for MEDLINE]


☐ 4: Melisku MF, Fox R, Vennik A. [Related Articles, Links](#)

 Reactivation of hepatitis C virus after chemotherapy for colon cancer.
Clin Oncol (R Coll Radiol). 2004 May;16(3):204-5.
PMID: 15191008 [PubMed - indexed for MEDLINE]


☐ 5: Sadava MR, Mayner R, Doniger J. [Related Articles, Links](#)

 A novel approach to develop anti-HIV drugs: adapting non-nucleoside anticancer chemotherapeutics.
Antiviral Res. 2004 Jan;61(1):1-18. Review.
PMID: 14670589 [PubMed - indexed for MEDLINE]


☐ 6: Antony S, Jayaraman M, Lago G, Kohlhaagen G, Kohn KW, Cushman M, Pommeroy Y. [Related Articles, Links](#)

 Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
Cancer Res. 2003 Nov 1;63(21):7428-35.
PMID: 14612542 [PubMed - indexed for MEDLINE]


☐ 7: Yokota S, Yokosawa N, Kubota T, Okabayashi T, Arata S, Fujii N. [Related Articles, Links](#)

 Suppression of thermotolerance in mumps virus-infected cells is caused by lack of HSP27 induction contributed by STAT-1.
J Biol Chem. 2003 Oct 24;278(43):41654-60. Epub 2003 Aug 13.
PMID: 12917439 [PubMed - indexed for MEDLINE]


☐ 8: Royal W 3rd, Dupont B, McGuire D, Chang L, Goodkin K, Ernst T, Post ML, Fish D, Pallouxi G, Ponclet J, Concha M, Aguzzo J, Singer E. [Related Articles, Links](#)

 Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy.
J Neurovirol. 2003 Jun;9(3):411-9.
PMID: 12775425 [PubMed - indexed for MEDLINE]

☐ 9: Dumortier J, Villarejo JJ, Ispaluz MG, Voennelle V, Beatrix O, Serrazec JY, Lombard-Bohas C. [Related Articles, Links](#)


 [Severe acute cytomegalovirus colitis after administration of irinotecan and raltitrexed chemotherapy]
Gastroenterol Clin Biol. 2003 Mar;27(3 Pt 1):347-8. French. No abstract available.
PMID: 12700527 [PubMed - indexed for MEDLINE]

☐ 10: Goldman F, Scandris D. [Related Articles, Links](#)

 An HIV treatment the world may never see.
Posit Aware. 2002 Mar-Apr;13(2):19-25. No abstract available.

BEST AVAILABLE COPY

PMID: 12001923 [PubMed - indexed for MEDLINE]

-  11: Vignu JA, Bieszczyk CK, Cleveland ES, Ma Y, Park JP, Mohandas TK, Craig RW.

Related Articles, Links



An MCL1-overexpressing Burkitt lymphoma subline exhibits enhanced survival on exposure to serum deprivation, topoisomerase inhibitors, or staurosporine but remains sensitive to 1-beta-D-arabinofuranosylcytosine.
Cancer Res. 2002 Feb 1;62(3):892-900.
PMID: 11830549 [PubMed - indexed for MEDLINE]



- 12: Ahmed M, Lock M, Miller CG, Fraser NW.

Related Articles, Links



Regions of the herpes simplex virus type 1 latency-associated transcript that protect cells from apoptosis in vitro and protect neuronal cells in vivo.
J Virol. 2002 Jan;76(2):717-29.
PMID: 11752162 [PubMed - indexed for MEDLINE]



- 13: Hambach J, Filer M, Dammann E, Batliner K, Stuck U, Heil G, Ganser A, Herrenstein B.

Related Articles, Links



Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
Bone Marrow Transplant. 2001 Oct;28(7):705-7. Review.
PMID: 11704795 [PubMed - indexed for MEDLINE]



- 14: Hung CL, Daniger J, Palini A, Snyder SW, Radanovich MF, Brady JN, Pantazis P, Sadelain MR.

Related Articles, Links



9-Nitrocamptothecin inhibits HIV-1 replication in human peripheral blood lymphocytes: a potential alternative for HIV-infection/AIDS therapy.
J Med Virol. 2001 Jul;64(3):238-44.
PMID: 11424110 [PubMed - indexed for MEDLINE]



- 15: Bowers M.

Related Articles, Links



Progressive multifocal leukoencephalopathy.
BETA. 1997 Sep;23-6.
PMID: 11364695 [PubMed - indexed for MEDLINE]



- 16: [No authors listed]

Related Articles, Links



PML update.
Crit Path AIDS Proj. 1997 Summer;(No 32):31.
PMID: 11364441 [PubMed - indexed for MEDLINE]



- 17: Learned J.

Related Articles, Links



Topotecan and PML: the limits of pharmaceutical industry research.
Notes Undergr. 1996 Sep;(No 33):1-3.
PMID: 11363913 [PubMed - indexed for MEDLINE]



- 18: Smart J.

Related Articles, Links



Making inroads on PML.
GMHC Treat Issues. 1996 May;10(5):10-2.
PMID: 11363582 [PubMed - indexed for MEDLINE]



- 19: Smart J.

Related Articles, Links



Topotecan research moves forward at last.
GMHC Treat Issues. 1995 Apr;9(4):1-3.
PMID: 11362363 [PubMed - indexed for MEDLINE]



- 20: [No authors listed]

Related Articles, Links



Topotecan now available for HIV, PML research.
AIDS Treat News. 1995 Apr 7;(no 220):4.
PMID: 11362319 [PubMed - indexed for MEDLINE]



- 21: [No authors listed]

Related Articles, Links



PML and a tale of two drug companies.
Notes Undergr. 1995 Winter;(no 29):4-6.
PMID: 11362283 [PubMed - indexed for MEDLINE]



- 22: Sadelain MR, Daniger J, Hung CL, Pantazis P.

Related Articles, Links

















9-nitrocamptothecin selectively inhibits human immunodeficiency virus type 1 replication in freshly infected parental but not 9-nitrocamptothecin-resistant U937 monocytoid cells.
AIDS Res Hum Retroviruses. 1999 Feb 10;15(3):239-45.
PMID: 10052754 [PubMed - indexed for MEDLINE]

Hong J, Nagar EE


Related Articles, Links

BEST AVAILABLE COPY


- 23:  The efficacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line.
J Neurovirol. 1998 Aug;4(4):451-6.
PMID: 9718138 [PubMed - indexed for MEDLINE]
- 24:  Moulton S, Panarasis P, Epstein JS, Sadovic MR. 9-Nitrocamptothecin inhibits tumor necrosis factor-mediated activation of human immunodeficiency virus type 1 and enhances apoptosis in a latently infected T cell clone.
AIDS Res Hum Retroviruses. 1998 Jan 1;14(1):39-49.
PMID: 9453250 [PubMed - indexed for MEDLINE]
- 25:  O'Reilly S. Efficacy of camptothecin in progressive multifocal leucoencephalopathy.
Lancet. 1997 Jul 26;350(9073):291. No abstract available.
PMID: 9242821 [PubMed - indexed for MEDLINE]
- 26:  Vollmer-Hause J, Young P, Ringelstein FB. Efficacy of camptothecin in progressive multifocal leucoencephalopathy.
Lancet. 1997 May 10;349(9062):1366. No abstract available.
PMID: 9149702 [PubMed - indexed for MEDLINE]
- 27:  Zhang JL, Sharma PL, Li CL, Deszue BJ, Pardee AB, Crumpacker CS. Topotecan inhibits human immunodeficiency virus type 1 infection through a topoisomerase-independent mechanism in a cell line with altered topoisomerase I.
Antimicrob Agents Chemother. 1997 May;41(5):977-81.
PMID: 9145855 [PubMed - indexed for MEDLINE]
- 28:  Potmesil M, Vardeman D, Kozielski AJ, Mendoza J, Stehlin JS, Giovarelli BC. Growth inhibition of human cancer metastases by camptothecins in newly developed xenograft models.
Cancer Res. 1995 Dec 1;55(23):5637-41.
PMID: 7585647 [PubMed - indexed for MEDLINE]
- 29:  Bodley AL, McGarry MW, Shapiro TA. Drug cytotoxicity assay for African trypanosomes and Leishmania species.
J Infect Dis. 1995 Oct;172(4):1157-9.
PMID: 7561203 [PubMed - indexed for MEDLINE]
- 30:  Bodley AL, Wani MC, Wall ME, Shapiro TA. Antitrypanosomal activity of camptothecin analogs. Structure-activity correlations.
Biochem Pharmacol. 1995 Sep 28;50(7):937-42.
PMID: 7575676 [PubMed - indexed for MEDLINE]
- 31:  Tsuda H, Takatsuki K, Ohno R, Masataka T, Okada K, Shirakawa S, Ohashi Y, Ota K. Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11). CPT-11 Study Group on Hematological Malignancy.
Br J Cancer. 1994 Oct;70(4):771-4.
PMID: 7917938 [PubMed - indexed for MEDLINE]
- 32:  Akutsu M, Suzuki K, Tsunoda S, Kano Y, Nishimura Y. [Effects of SN-38 in combination with other anticancer agents against Dauji cells]
Gan To Kagaku Ryoho. 1994 Aug;21(10):1607-11. Japanese.
PMID: 8060135 [PubMed - indexed for MEDLINE]
- 33:  Gihene MA, Tucker K, Richardson J, Uhr JW, Vitetta ES. Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail.
Blood. 1994 Aug 1;84(3):702-7.
PMID: 7519071 [PubMed - indexed for MEDLINE]
- 34:  Mukono T, Nakahara K, Takatsuka Y, Shimotakahara S, Usumonoya S, Hayada S, Tokimasa M, Arima T. [Successful treatment of chemotherapy-resistant adult T cell leukemia/lymphoma by irinotecan hydrochloride (CPT-11)]
Rinsho Ketsu. 1994 Jan;35(1):42-8. Japanese.
PMID: 8139101 [PubMed - indexed for MEDLINE]
- 35:  Jardine D, Tachedjian G, Locantore S, Birch G.

 Cellular topoisomerase I activity associated with HIV-1.
AIDS Res Hum Retroviruses. 1993 Dec;9(12):1245-50.
PMID: 8142141 [PubMed - indexed for MEDLINE]


☐ 36: [Priel E, Allain F, Cheschevsky G, Reutemann D, Aboud M, Segal S](#) [Related Articles](#), [Links](#)

 Inhibition of retrovirus-induced disease in mice by camptothecin.
J Virol. 1993 Jun;67(6):3624-9.
PMID: 8388515 [PubMed - indexed for MEDLINE]


☐ 37: [Li CL, Zhang LJ, Dzau VJ, Crumpacker CS, Pardee AB](#) [Related Articles](#), [Links](#)

 Three inhibitors of type I human immunodeficiency virus long terminal repeat-directed gene expression and virus replication.
Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1839-42.
PMID: 8446597 [PubMed - indexed for MEDLINE]

☐ 38: [Dong CZ, Abdulhake S, Fong MP, Bridghe J, Albrecht T](#) [Related Articles](#), [Links](#)

 Modulation of the frequency of human cytomegalovirus-induced chromosome aberrations by camptothecin.
Virology. 1992 Jul;189(1):397-401.
PMID: 1318615 [PubMed - indexed for MEDLINE]

☐ 39: [Ebbesen P, Petersen PM, Jensen A, Narskov-Lauritsen N, Nielsen CM, Philipsen HP, Arenholt-Bindslev D, Nara P](#) [Related Articles](#), [Links](#)

 Explants of human oral epithelium exposed to viruses and cancer chemotherapeutics.
J Oral Pathol Med. 1989 Sep;18(8):481-4.
PMID: 2558179 [PubMed - indexed for MEDLINE]

Display: **Summary**

Show 50

Sort by

Send to

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Jan 19 2006 11:31:52